WuXi PharmaTech participated in the $7 million A round of ApoGen Biotechnologies, a Seattle startup targeting drug resistance in cancer cells. ApoGen is focusing on an antiviral component of the human innate immune system – the APOBEC cytidine deaminases – which are enzymes that are implicated in tumor mutations and lead to drug resistance. ApoGen was formed by the Accelerator Corporation of Seattle and New York, a 13-year-old incubator for drug development companies.
